Close

Aetna (AET) Still Weighing Whether to Cover Sarepta's (SRPT) Exondys 51 - Bloomberg

Go back to Aetna (AET) Still Weighing Whether to Cover Sarepta's (SRPT) Exondys 51 - Bloomberg

Sarepta (SRPT) PT Raised to $72 at Wedbush Ahead of US Launch of Exondys 51

October 10, 2016 6:52 AM EDT

Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $72.00 (from $66.00) ahead of the US Launch of Exondys 51.

Behanna commented, "With the first patient dosed with commercial Exondys 51 this week, we have built out our model to look at US potential penetration into each segment of boys amenable to therapy... More

Anthem (ANTM) Dragging Feet on Sarepta's (SRPT) Exondys 51 is Likely Negotiating Tactic - Oppenheimer

October 7, 2016 3:14 PM EDT

Oppenheimer affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $76 as Anthem said EXONDYS 51 wasn't medically necessary earlier today, putting pressure on SRPT shares.

The firm commented: Anthem's medical policy took the position that eteplirsen (EXONDYS 51) is "investigational and not... More

Humana (HUM) says still weighing whether or not to cover Sarepta's Exondys 51 - Bloomberg

October 7, 2016 2:52 PM EDT

Humana (NYSE: HUM) says still weighing whether or not to cover Sarepta's Exondys 51 - Bloomberg

... More

UnitedHealth Group (UNH) says planning to cover Sarepta's (SRPT) Exondys 51 - Reuters.

October 7, 2016 2:29 PM EDT

UnitedHealth Group (NYSE: UNH) says planning to cover Sarepta Therapeutics (Nasdaq: SRPT) Exondys 51, according to Reuters headlines.

Those covering Exondys 51 also includes Cigna (NYSE: CI), while Humana (NYSE:... More

Sarepta Therapeutics (SRPT) Shares Make Strong Move Off Session Lows

October 7, 2016 2:26 PM EDT

Sarepta Therapeutics (NASDAQ: SRPT) shares are seeing a slight pop higher. Baird was out in defense of the stock this afternoon.

... More

Baird Says No Change to Sarepta (SRPT) Outlook Amid Anthem Slight

October 7, 2016 1:06 PM EDT

Baird analyst Brian Skorney said their is no change to his outlook on Sarepta Therapeutic (NASDAQ: SRPT) amid news Anthem, the nation's second-largest insurer by number of covered lives, issued a coverage policy this morning categorizing Exondys 51 as "not medically necessary."... More

Sarepta Therapeutics (SRPT) Falls as Anthem says Exondys 51 Not Medically Necessary

October 7, 2016 10:39 AM EDT

Sarepta Therapeutics (NASDAQ: SRPT) ticks lower after Anthem says Exondys 51 not medically necessary. Shares are down 3.2%.

Anthem's position statement:

"The use of eteplirsen is considered investigational and not medically necessary for all indications, including but not limited to the treatment of Duchenne muscular dystrophy."

LINK

... More